Literature DB >> 9401714

Disruption of the Kamin blocking effect in schizophrenia and in normal subjects following amphetamine.

S H Jones1, D Hemsley, S Ball, A Serra.   

Abstract

The Kamin blocking effect (KBE) is an established animal learning paradigm measuring selective processing, in which reduced blocking reflects allocation of greater processing resources to non-relevant information. Two KBE tasks are described below. Results from studies using the first (between-subjects) task indicate that KBE is abolished in acute schizophrenics with positive psychotic symptoms. It is also abolished in the relatives of schizophrenic subjects, although interpretation of this finding is hampered by poor performance of subjects in the control condition. The second (within-subjects) task indicated abolition of KBE in schizophrenic patients with positive psychotic symptoms. Administration of acute amphetamine to normal human subjects did not significantly disrupt performance on the first task. Whilst for the second task, although blocking was limited to placebo subjects, overall pre-exposure effects are not sufficiently strong to indicate specific drug effects.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9401714     DOI: 10.1016/s0166-4328(97)02312-7

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  10 in total

1.  A comparison of latent inhibition and learned irrelevance pre-exposure effects in rabbit and human eyeblink conditioning.

Authors:  M Todd Allen; Lori Chelius; Vivek Masand; Mark A Gluck; Catherine E Myers; Geoffrey Schnirman
Journal:  Integr Physiol Behav Sci       Date:  2002 Jul-Sep

2.  Disruption of the US pre-exposure effect and latent inhibition in two-way active avoidance by systemic amphetamine in C57BL/6 mice.

Authors:  Tilly Chang; Urs Meyer; Joram Feldon; Benjamin K Yee
Journal:  Psychopharmacology (Berl)       Date:  2006-12-19       Impact factor: 4.530

3.  Transient disruption of attentional performance following escalating amphetamine administration in rats.

Authors:  Robyn L Kondrad; Joshua A Burk
Journal:  Psychopharmacology (Berl)       Date:  2004-10       Impact factor: 4.530

4.  Kamin blocking is associated with reduced medial-frontal gyrus activation: implications for prediction error abnormality in schizophrenia.

Authors:  Paula M Moran; Jennifer L Rouse; Benjamin Cross; Rhiannon Corcoran; Martin Schürmann
Journal:  PLoS One       Date:  2012-08-31       Impact factor: 3.240

5.  Attention to irrelevant cues is related to positive symptoms in schizophrenia.

Authors:  Richard Morris; Oren Griffiths; Michael E Le Pelley; Thomas W Weickert
Journal:  Schizophr Bull       Date:  2012-01-20       Impact factor: 9.306

6.  Irrelevance by inhibition: Learning, computation, and implications for schizophrenia.

Authors:  Nathan Insel; Jordan Guerguiev; Blake A Richards
Journal:  PLoS Comput Biol       Date:  2018-08-01       Impact factor: 4.475

7.  Smooth pursuit and visual occlusion: active inference and oculomotor control in schizophrenia.

Authors:  Rick A Adams; Laurent U Perrinet; Karl Friston
Journal:  PLoS One       Date:  2012-10-26       Impact factor: 3.240

8.  When to hold that thought: an experimental study showing reduced inhibition of pre-trained associations in schizophrenia.

Authors:  Zhimin He; Helen J Cassaday; S Bert G Park; Charlotte Bonardi
Journal:  PLoS One       Date:  2012-07-30       Impact factor: 3.240

9.  Cognitive mechanisms of change in delusions: an experimental investigation targeting reasoning to effect change in paranoia.

Authors:  Philippa Garety; Helen Waller; Richard Emsley; Suzanne Jolley; Elizabeth Kuipers; Paul Bebbington; Graham Dunn; David Fowler; Amy Hardy; Daniel Freeman
Journal:  Schizophr Bull       Date:  2014-07-21       Impact factor: 9.306

Review 10.  The prediction-error hypothesis of schizophrenia: new data point to circuit-specific changes in dopamine activity.

Authors:  Samuel J Millard; Carrie E Bearden; Katherine H Karlsgodt; Melissa J Sharpe
Journal:  Neuropsychopharmacology       Date:  2021-09-29       Impact factor: 7.853

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.